A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.

@article{Guskey2010ACR,
  title={A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.},
  author={Michael T Guskey and Brian T. Tsuji},
  journal={Pharmacotherapy},
  year={2010},
  volume={30 1},
  pages={80-94}
}
Resistance to antibiotics among gram-positive bacteria, especially enterococci and staphylococci, has led to the need to develop new antibiotics. Vancomycin, a glycopeptide antibiotic, has been used for over 3 decades to treat serious methicillin-resistant Staphylococcus aureus infections. The increased frequency of multidrug-resistant bacteria, especially vancomycin-resistant strains, has focused interest on three new lipoglycopeptides for the treatment of infections caused by gram-positive… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 26 extracted citations

Oritavancin: A Long-Half-Life Lipoglycopeptide.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2015
View 1 Excerpt

Similar Papers

Loading similar papers…